Lunai Bioworks (RENB) Stock Analysis

What Lunai Bioworks does

Lunai Bioworks, Inc. functions as a pre-clinical stage biotechnology enterprise, concentrating its efforts on pioneering genetically modified cell and immunotherapeutic platforms. These advanced technologies are aimed at providing treatments for a range of infectious diseases and oncological conditions. The company's development pipeline features several candidates, specifically ENOB-HV-01, ENOB-HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. Founded on January 18, 2011, by Rene Sindlev and Serhat Gumrukcu, Lunai Bioworks maintains its corporate base in Los Angeles, California.

Key metrics

ETFs linked to RENB

Broad-market and Healthcare sector ETFs an investor holding Lunai Bioworks is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RENB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Lunai Bioworks?

Lunai Bioworks trades under the ticker RENB on NASDAQ.

Which exchange is RENB listed on?

RENB is listed on NASDAQ.

What sector does Lunai Bioworks operate in?

Lunai Bioworks is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RENB in a portfolio?

PortView shows RENB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.